Advance in basic and clinical research of Xuezhikang Capsule: A commentary on the Chinese coronary secondary prevention study

Chinese Journal of Integrative Medicine

Volumn 12, Issue 2, 2006, Pages 85-87

  Lu, Zong Liang ^a  

^a FUWAI HOSPITAL   (China)

Author keywords

[No Author keywords available]

Indexed keywords

CHINESE DRUG; LIPID; PRAVASTATIN; STATIN; UNCLASSIFIED DRUG; XUEZHIKANG EXTRACT;

CHINESE MEDICINE; CLINICAL RESEARCH; CLINICAL TRIAL; CORONARY ARTERY BYPASS GRAFT; CORONARY ARTERY DISEASE; DRUG DOSE REGIMEN; DRUG HYPERSENSITIVITY; DRUG SAFETY; FOLLOW UP; GASTROINTESTINAL SYMPTOM; HEART INFARCTION; HUMAN; LIPID BLOOD LEVEL; NOTE; PERCUTANEOUS CORONARY INTERVENTION; PRIORITY JOURNAL; TREATMENT OUTCOME;

ANTI-INFLAMMATORY AGENTS; CAPSULES; CHINA; CORONARY DISEASE; DRUGS, CHINESE HERBAL; HUMANS;

EID: 33745844800     PISSN: 16720415     EISSN: None     Source Type: Journal    
DOI: 10.1007/BF02857352     Document Type: Note

References (5)

1. China Coronary Secondary Prevention Study (CCSPS) Collaborative Group for China Coronary Secondary Prevention Using Xuezhikang. China coronary secondary prevention study (CCSPS). Chin J Cardiol 2005; 33(2): 109-115.
2. Kou WR. Review on Bases and clinics of Xuezhikang Capsule. Chin J Intern Med 1998; 37(6): 364-367.
3. Scandinavian Simvastatin Survival Study Group. Randomized trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S). Lancet 1994;344: 1383-1389.
4. Sacks FM, Pfeffer MA, Moye LA, et al. The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. N Engl J Med 1996;335: 1001-1009.
5. The LIPID Study Group. Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels. N Engl J Med 1998;339: 1349-1357.